Denville Partners

Executive Search: Biotech, Pharma, MedTech and related nonprofits. We help drive drug development and build mission driven teams. Rare & common disorders.

[Jason Ford @JasonFord6]

Q4 and early 2027 hiring continues year-round. Search firms bring comp insight, protect confidentiality, maintain momentum, and negotiate Q1 bonuses, buyouts & equity. Partners through the calendar, not just CVs. #Hiring

[Jason Ford @JasonFord6]

Current open non-profit opportunities:

VP of Corporate Development and Innovation (ALS)

CEO - rare and ultra rare diseases

COO - rare diseases, operational and finance

We are Denville Partners working at the nexus of nonprofit impact and biotech innovation.

[Denville Partners @PartnerInSearch]

This is big news and outstanding progress for patients. While Rare Disease are now getting long overdue attention, the focus needs to stay on the ecosystem for the long-term.

[FDA Drugs and Biologics @FDADrugs]

The FDA today launched the Rare Disease Framework Initiative to reimagine rare disease drug development.

The new framework will adapt aspects of the agency’s long-standing approach designed for larger diseases. It will adopt an optimized, fit-for-purpose framework for rare disease drug development that considers the nuances of a specific disease, patient needs, product type, and attainable evidence. https://t.co/cngtfmvdMv

FDA will host a meeting on Oct. 28 at the White Oak campus to collect feedback on the Rare Disease Framework Initiative from patients, disease advocates, industry, and other stakeholders. https://t.co/0ynT0EXG0s

[Jason Ford @JasonFord6]

Nonprofit CEOs and EDs must lead technology, not just manage it. AI, data and digital fundraising can amplify mission and unlock growth. The wrong hire can cost millions. #ExecutiveSearch #NonprofitLeadership

[Denville Partners @PartnerInSearch]

@adamfeuerstein We split the blame equally between Josh McDaniels’ telegraphic play calling and Drake Maye’s throwing ducks off his back foot.

[Denville Partners @PartnerInSearch]

We love exploring and leveraging new technologies. Instead of debating end of world scenarios, let's take advantage of what is available to make life better for everyone.

[Jason Ford @JasonFord6]

A milestone for AI-enabled drug discovery: Insilico’s rentosertib for IPF has entered Phase III, with the first patient dosed. No AI-designed drug has reached approval yet; but the field is moving forward. #Biotech

[Denville Partners @PartnerInSearch]

We are a search firm but technology is an interesting topic. We have had clients openly push back on exploring new technologies that would clearly amplify the org into the future. While uncomfortable, first (early) mover advantage is real. #nonprofit #blockchain #AI

[Jason Ford @JasonFord6]

Tomorrow’s nonprofit leaders must lead technology transformation: not simply manage it. AI, data, and digital fundraising can amplify mission when guided by purpose. #NonprofitLeadership #SuccessionPlanning

[Jason Ford @JasonFord6]

Succession is an opportunity to hire for the future: not replace the past. Seek leaders who scale impact, embrace technology, and build partnerships that move the mission forward. #NonprofitLeadership #SuccessionPlanning

[Alltrna @alltrna]

Throughout her career caring for children and developing medicines for rare diseases, Nerissa Kreher has met many families searching for a treatment option for their child or loved one.

For many rare and ultra-rare diseases, small patient populations can make studying each disease separately difficult. Basket trials offer another potential path, bringing together people with different diseases that share the same underlying mutation and relevant clinical characteristics.

On Labiotech’s Beyond Biotech podcast, Nerissa discusses why engineered tRNA medicines may be well suited to this approach, the clinical development of AP003, the first tRNA therapeutic to enter clinical trials, and the evidence needed to support future basket trials.

Listen here: https://t.co/XSpD6McglG

[Jason Ford @JasonFord6]

Sometimes a nonprofit’s most promising program belongs outside it. A dedicated spin-out can bring focused capital, speed, and risk tolerance: while the nonprofit retains equity, a seat at the table, and the upside.

[CAMP4 Therapeutics @camp4tx]

Today, we announced our Q2 2026 financial results and corporate highlights. Read more in our press release: https://t.co/DSbDxfX7CA

[Jason Ford @JasonFord6]

ALS-TDI’s patient-driven model connects patient data, iPSC models and drug discovery. Its copper-complex lead, TDI-1831, is advancing through IND-enabling studies. #ALSResearch #RareDisease

[Denville Partners @PartnerInSearch]

@RosserJobs We agree with the post and could add five more reasons.

Point 2 is underrated. A good search firm acts as a public relations firm: building awareness, positive perception, and helping build the brand. The next search for a similar skill set should be easier.

[Bio Protocol @BioProtocol]

What if the money for research reached scientists in weeks instead of years?

American scientists now spend nearly half their time on paperwork. Some grants take two years to approve.

The White House just called this out and asked for the biggest rebuild of science since 1945.

It wants funding to reach researchers directly, young scientists backed early, and people judged on their work, not their place in line. It also says AI will change how discovery happens, but the best models will stall inside institutions built for the last century.

This is the model onchain science already runs. A scientist with an agent fleet and an onchain treasury can run programs that once needed a whole institution.

The funding comes straight from the people who want the work done. Every step is recorded in the open. The scientist sets the direction, and the infrastructure carries it out.

The report is describing a future we are already building at Bio.

[ULF @UlfUnited]

Call for Research Proposals! Each year, the ULF welcomes researchers from around the world to submit their research project proposals for funding consideration. Applications are now being accepted through August 12, 2026. For more details, visit: https://t.co/DFFsyBYCQK

[Denville Partners @PartnerInSearch]

This is beg news !!

[Bio Protocol @BioProtocol]

DeSci is on @RobinhoodApp

BIO is now tradable on Robinhood ↓

[Denville Partners @PartnerInSearch]

@RosserJobs Great post. We would argue that’s true for almost any position that’s critical in nature regardless of title.

[CAMP4 Therapeutics @camp4tx]

Excited to kick off our #CAMP4Fireside Series to highlight the people behind CAMP4. Hear from our CEO, Josh Mandel-Brehm, as he shares a glimpse into what’s ahead. Watch the video, and learn more about our mission here: https://t.co/oHsGTjJJRo

[Jason Ford @JasonFord6]

Biotech startups offer a 'resilience dividend.' Even if a venture fails, the experience of building from scratch is resume gold. These unique skills make it a low-risk career move in the long run.

#BiotechCareers #Resilience #DenvillePartners #Leadership